FACC (Austria)

Sepsis is defined as a dysregulated host response to an infection, leading to life-threatening organ dysfunction. While sepsis is most commonly the result of a bacterial infection, it may also be caused by viral pathogens. The aim of this study was to describe differences in organ dysfunction patterns and inflammatory markers between bacterial and viral sepsis. In this prospective multicenter cohort study, adults meeting SEPSIS-3 criteria were recruited from four Austrian ICUs between 1 August 2021 and 1 April 2024, excluding those who were immunocompromised within the preceding 12 months. Ninety patients were enrolled, of whom 57 had bacterial and 33 viral sepsis. Inflammatory markers, including IL-6 and PCT, were higher at ICU admission in bacterial sepsis. Adjusted linear regression confirmed bacterial etiology as the only significant predictor of higher 48 h peak IL-6 and PCT values. Patients with viral sepsis typically fulfilled SEPSIS-3 criteria through respiratory and cardiovascular SOFA components, while other organ dysfunctions were less frequent. Significant differences in the phenotype of bacterial and viral sepsis were observed, characterized by distinct inflammatory profiles and differing patterns of organ dysfunction. These findings may support the improved differentiation of bacterial and viral etiologies in sepsis.

4166 Background: Pancreatic ductal adenocarcinoma (PDAC) frequently presents at late stages, resulting in increased mortality. Early detection is crucial for enhancing survival rates; however, available screening methods are limited. This gap underscores the critical need for advancements in early PDAC detection. To address this, Wholomics developed a proprietary early detection assay, leveraging molecular signatures found in the blood, and has further validated its efficacy through a comprehensive blinded validation study. Methods: Wholomics conducted retrospective analysis of serum samples from the Amsterdam UMC Liquid Biopsy Center and the Bank of Biological Material of the Masaryk Memorial Cancer Institute. A training cohort included 290 control subjects, 12 patients with a confirmed diagnosis of chronic pancreatitis, and 71 patients with a histopathologically confirmed diagnosis of PDAC (20 stage I, 30 stage II, 13 stage III, 8 stage IV). A blinded validation cohort comprised samples from 20 control subjects, 24 patients with non-cancerous conditions (5 with benign tumors, 10 with IPMNs, 9 with chronic pancreatitis), and 60 patients with histologically confirmed PDAC. Peripheral blood samples of cancer patients were drawn before surgery or treatment. Wholomics used its proprietary NMR-based technology to quantitatively analyze serum samples. Disease-specific molecular signatures were identified and used to develop a computational biomarker specific to PDAC. A comparative analysis via 10-fold cross-validation and a blinded validation were conducted. The accuracy, specificity and sensitivity are reported. Results: In this study, a dual-cohort design, comprising both a training and a blinded validation cohort, was utilized to assess the capability of the Wholomics technology in detecting cancer-specific molecular signatures. In the training cohort, a 94.6% accuracy was achieved in distinguishing PDAC patients from non-cancer controls. A specificity of 95.7% and sensitivity of 90.7% were reached. A similar performance was observed in the blinded validation cohort, where the blood-based test accurately differentiated PDAC patients from controls with an accuracy of 92.5%. In more detail, a specificity of 95% (noting a single false positive) and a sensitivity of 91.7% were achieved. Conclusions: The collective findings of this research indicate that utilizing disease-specific molecular markers in peripheral blood offers a highly accurate method for differentiating between PDAC patients, healthy subjects, and those with pre-cancerous diseases. Should future studies across broader cohorts corroborate these results, this testing approach has potential for consideration as a screening mechanism for PDAC, aiming to facilitate early detection and consequently enhance patient prognoses.

Abstract The tensile behavior of a flexible epoxy resin reinforced with knitted reinforcements from various fiber materials was comprehensively studied in the wale and course direction. By measuring dry yarns, temperature‐treated yarns, dry knitted fabrics and flexible composites, the effect of the fiber material and the knitted fabric on the tensile properties was analyzed. The interlock knit structure strongly affected the deformation behavior of the flexible composites which differed significantly from the dry knitted fabrics. The deformation behavior of the flexible composites was monitored using digital image correlation which revealed the formation of cracks and high local strain differences in the course direction for all fiber materials. This was linked to fiber‐matrix debonding by scanning electron microscope observations. In the wale direction, the deformation of the knitted structure under tensile load led to plastic deformation of the matrix material. Overall, with yarns from recycled thermoplastic fibers, a higher maximum stress and strain at break was achieved compared to bio‐based fibers. However, irreversible damage occurred for all fiber materials at similar strain values.Highlights Tensile tests on yarns, knitted fabrics and flexible composites. Investigation of the effect of fiber material on mechanical properties. High local strain differences in composites due to knitted structure. Fiber‐matrix debonding in course direction. Plastic deformation of the matrix material in the wale direction.

BackgroundInvasive lobular carcinoma (ILC) represents the second most common type of invasive breast cancer (BC). Although ILC generally have good prognostic properties (positive estrogen receptor, ER, low tumor grade), they are generally diagnosed at a more advanced stage. The data on the axillary lymph node status in ILC compared to invasive ductal carcinoma (IDC) are considered controversial. Therefore, the aim of this study was to compare the pathological node stage (pN) between ILC and IDC in an Austria-wide register.MethodsData of the Clinical Tumor Register (Klinisches TumorRegister, KTR) of the Austrian Association for Gynecological Oncology (AGO) were retrospectively analyzed. Patients with primary early BC, invasive lobular or ductal, diagnosed between January 2014 and December 2018, and primary surgery were included. A total of 2127 tumors were evaluated and compared in 2 groups, ILC n = 303, IDC n = 1824.ResultsA total of 2095 patients were analyzed in the study. In the multivariate analysis, pN2 and pN3 were observed significantly more frequently in ILC compared with IDC (odds ratio, OR 1.93; 95% confidence interval, CI 1.19–3.14; p = 0.008 and OR 3.22; 95% CI: 1.47–7.03; p = 0.003; respectively). Other factors associated with ILC were tumor grades 2 and 3, positive ER, and pathological tumor stage (pT) 2 and pT3. In contrast, concomitant ductal carcinoma in situ, overexpression of the human epidermal growth factor receptor 2 (HER2), and a moderate and high proliferation rate (Ki67) were found less frequently in ILC.ConclusionThe data show an increased risk of extensive axillary lymph node metastasis (pN2/3) in ILC.

In Kap. 2 fehlten die Literaturzitate. Diese sind in Kap. 2 aktualisiert worden. Die korrigierte Version des Kapitels ist verfügbar unter:

Cardiovascular disease is the most common cause of morbidity and mortality worldwide, and the risk is heightened in the presence of obesity. We review semaglutide, a drug recently approved for chronic weight management in adults with obesity or who are overweight. On 4 June 2021, the US Food and Drug Administration approved semaglutide injection at 2.4 mg once weekly for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes mellitus, or high cholesterol. This subcutaneous injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014. The drug is indicated for weight management in patients with a BMI of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater. Semaglutide offers adults with obesity or overweight a new treatment in conjunction with a weight management program consisting of reduced calorie diet and increased physical activity.

Background:There are wide number of diseases of almost every system in the body which can affect heart in a number of different ways including increasing demands on the heart ,ventricular dysfunction ,rhythm abnormalities ,valve abnormalities ,pulmonary pressures and lot more.Cardiac involvement in systemic diseases is usually silent or oligosymptomatic and includes different pathophysiological mechanisms such as myocardial inflammation, infarction ,subendocardial vasculitis,valvular disease and different patterns of fibrosis. Objective : To study association between systemic illnesses (hematological, endocrinal , renal) and cardiac function abnormalities as ventricular function,cardiac dimensions ,pulmonary artery pressure and pericardial effusion,for early diagnosis and treatment to decrease morbidity and mortality in patient with systemic illness. Design/Method:It was a cross sectional,descriptive study The present study was conducted in the Department of Pediatrics, LLRM Medical College,Meerut,Uttar Pradesh over a period of 1 year (June 2019-June 2020) Results: Cardiac findings in all three groups show ECG abnormalities and echocardiographic changes compared to general population. ECG abnormalities were prolonged PR interval and sinus tachycardia while echocardiographic changes mainly left ventricular(LV) dilatation and hypertrophy ,increased cardiac output ,ventricular dysfunction and pulmonary arterial hypertension(PAH),were noted in a significant proportion of patients. Conclusion:Systemic illnesses affect cardiac parameters in various ways including prolonged PR interval,cardiac dilatation,chamber hypertrophy ,high cardiac output,high cardiac index ,PAH and ventricular dysfunction.